Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • NeoGenomics (NGNM) Posts Second Quarter of YoY Increases, Reiterates Swing to Profit Q4 Guidance 0 comments
    Oct 19, 2011 5:54 PM | about stocks: NEO

    NeoGenomics Inc., a leading provider of cancer-focused genetic testing services, today reported its results for the third quarter 2011.

    The company reported quarterly revenue at $11.3 million, an increase of 30 percent compared to the $8.7 million reported in the third quarter 2010.

    Gross margin remained essentially flat at 44.8 percent in the 2011 quarter compared to 44.7 percent reported in last year’s third quarter.

    NeoGenomics reported a net loss for the quarter of $143,000, or ($0.00) per share, compared to a net loss of $1.1 million, or ($0.03) per share, in the third quarter 2010.

    Doug VanOort, the company’s chairman and CEO, detailed the company’s growth and the focus driving it.

    “For the second quarter in a row, we posted the largest year over year and sequential increases in quarterly revenue in our corporate history. We are especially pleased with the approximately $850,000, or 8 percent, sequential growth in revenue versus the second quarter as normal seasonal reductions were offset by strong organic growth,” VanOort stated in the press release. “Continued increases in the number of new clients combined with additional work from existing clients is encouraging. Our focus on customer service, launch of innovative products and services, and deployment of extensive training and development programs has allowed our sales and marketing team to become more productive.”

    VanOort said the company will maintain its focus on initiatives to improve gross margin. The company also reiterates previous guidance that it expects to return to profitability in the fourth quarter, with revenue of approximately$11.4 million – $12.0 million.

    “We continue to invest in initiatives to grow our business. We are opening a small lab facility in Tampa, FL to attract additional laboratory technologists to help keep up with growth and to reduce the number of tests we have to send out. Our pace of new test development has increased markedly over previous years and we will have launched twelve new molecular genetic tests by year end,” VanOort stated. “In addition, we have begun to expand our immunohistochemistry product line, and are investing in new capabilities for digital pathology and image analysis. We believe these initiatives, together with our sales, marketing, and business development programs, will allow us to continue a high level of revenue growth.”

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

     

    Stocks: NEO
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.